文献速递中毒与环境急症消化、代谢与肾脏急症

美国初级保健诊所提供成瘾治疗的估计临床结局与成本效果

Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics.
PubMed 文献 · JAMA Netw Open · 2023-04-03
一句话结论模拟模型显示,初级保健诊所整合丁丙诺啡处方与减害工具包可延长寿命、降低后遗症相关死亡33%,具有成本效果。

该建模研究使用REDUCE微观模拟模型,模拟225万注射阿片类药物者,比较三种策略:常规转诊(现状)、初级保健现场丁丙诺啡处方转诊场外减害工具包(BUP)、现场丁丙诺啡处方加减害工具包(BUP+HR)。BUP+HR较现状降低后遗症相关死亡33%,每增加生命年成本34400美元,具有成本效果;5年时间范围内每个初级保健诊所约花费13000美元。作者认为应将成瘾服务整合入初级保健作为医疗系统优先事项。

要点

  • 模拟队列225万人,BUP+HR较现状降低后遗症相关死亡33%,每增加生命年成本34400美元。
  • BUP+HR每人的贴现终身成本高于现状,但为优势策略,具有成本效果。
  • 5年时间范围内,BUP+HR使每个初级保健诊所花费约13000美元。
  • BUP和BUP+HR分别延长贴现预期寿命0.16年和0.17年。
  • 现状策略每人贴现成本203500美元(95%可信区间203000-222000美元),获得6.56个贴现生命年。

适用人群与场景

  • 美国注射阿片类药物者,模拟队列225万人,反映美国注射阿片类药物者的年龄和性别分布。

处置流程与药物剂量

  • 策略1(现状):初级保健提供者服务,外部转诊至成瘾治疗。
  • 策略2(BUP):初级保健提供者服务加现场丁丙诺啡处方,转诊至场外减害工具包。
  • 策略3(BUP+HR):初级保健提供者服务加现场丁丙诺啡处方和减害工具包。

研究设计与关键结果

  • 建模研究:使用REDUCE微观模拟模型,模拟225万人,比较三种策略,模型输入来自临床试验和观察性队列,成本年贴现率3%,从改良医疗部门视角评估终身成本效果,模型模拟开始于2021年1月1日,运行整个队列终身。
  • 现状策略:每人贴现生命年6.56,贴现成本203500美元(95%可信区间203000-222000美元)。
  • BUP策略:较现状延长贴现预期寿命0.16年。
  • BUP+HR策略:较现状延长贴现预期寿命0.17年,降低后遗症相关死亡33%。
  • BUP和BUP+HR每人的平均贴现终身成本均高于现状策略;BUP+HR为优势策略。
  • BUP+HR较现状具有成本效果,增量成本效果比为每生命年34400美元。
  • 5年时间范围内,BUP+HR使每个初级保健诊所花费约13000美元。

证据类型、等级与局限

  • 证据类型:建模研究(微观模拟模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,将成瘾服务整合入初级保健诊所应成为医疗系统的优先事项。
  • 该建模研究提示,初级保健整合成瘾服务可改善临床结局并适度增加成本。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: US primary care practitioners (PCPs) are the largest clinical workforce, but few provide addiction care. Primary care is a practical place to expand addiction services, including buprenorphine and harm reduction kits, yet the clinical outcomes and health care sector costs are unknown.

OBJECTIVE: To estimate the long-term clinical outcomes, costs, and cost-effectiveness of integrated buprenorphine and harm reduction kits in primary care for people who inject opioids.

DESIGN, SETTING, AND PARTICIPANTS: In this modeling study, the Reducing Infections Related to Drug Use Cost-Effectiveness (REDUCE) microsimulation model, which tracks serious injection-related infections, overdose, hospitalization, and death, was used to examine the following treatment strategies: (1) PCP services with external referral to addiction care (status quo), (2) PCP services plus onsite buprenorphine prescribing with referral to offsite harm reduction kits (BUP), and (3) PCP services plus onsite buprenorphine prescribing and harm reduction kits (BUP plus HR). Model inputs were derived from clinical trials and observational cohorts, and costs were discounted annually at 3%. The cost-effectiveness was evaluated over a lifetime from the modified health care sector perspective, and sensitivity analyses were performed to address uncertainty. Model simulation began January 1, 2021, and ran for the entire lifetime of the cohort.

MAIN OUTCOMES AND MEASURES: Life-years (LYs), hospitalizations, mortality from sequelae (overdose, severe skin and soft tissue infections, and endocarditis), costs, and incremental cost-effectiveness ratios (ICERs).

RESULTS: The simulated cohort included 2.25 million people and reflected the age and gender of US persons who inject opioids. Status quo resulted in 6.56 discounted LYs at a discounted cost of $203 500 per person (95% credible interval, $203 000-$222 000). Each strategy extended discounted life expectancy: BUP by 0.16 years and BUP plus HR by 0.17 years. Compared with status quo, BUP plus HR reduced sequelae-related mortality by 33%. The mean discounted lifetime cost per person of BUP and BUP plus HR were more than that of the status quo strategy. The dominating strategy was BUP plus HR. Compared with status quo, BUP plus HR was cost-effective (ICER, $34 400 per LY). During a 5-year time horizon, BUP plus HR cost an individual PCP practice approximately $13 000.

CONCLUSIONS AND RELEVANCE: This modeling study of integrated addiction service in primary care found improved clinical outcomes and modestly increased costs. The integration of addiction service into primary care practices should be a health care system priority.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Jawa R, Tin Y, Nall S, et al. Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics. JAMA Netw Open. 2023. PMID: 37043198. doi:10.1001/jamanetworkopen.2023.7888

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。